Umoja Biopharma, Inc. (Umoja), the clinical-stage leader of in vivo and off-the-shelf cell therapies that aim to realize the full reach and promise of CAR-T cells, today announced that members of management will participate in a fireside chat and 1x1 investor meetings at the 7th Annual Evercore ISI HealthCONx Conference,

SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage

Aura Biosciences is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. Our lead candidate, bel-sar (AU-011), is currently in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer.